AMGLIDIA 6 mg/ml, oral suspension bottle, 30 ml
Active ingredients: Glyburide
Commercialized according to BDPMDispensing in France: Prescription only
Oral suspensionbottle, 30 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AMGLIDIA 6 mg/mL, suspension buvable
- Pharmaceutical form
- suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) en verre brun avec fermeture de sécurité enfant de 30 ml avec adaptateur pour seringue avec seringue graduée pour administration orale de 1 ml
- Marketing authorisation holder
- AMMTEK
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Jun 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63618451CIP73014993CIP133400930149935Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLIBENCLAMIDEsuspension | 6 mg · 1 mL de suspension | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.